HGSI - Human Genome Sciences, Inc

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.

Clinical Development Pipeline

The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company’s primary focus is rapid progress toward the commercialization of our two lead products, Albuferon for hepatitis C, and LymphoStat-B for lupus. We have entered into collaboration agreements with two of the world’s leading pharmaceutical companies for the co-development and co-commercialization of these products. Our Albuferon collaborator is Novartis. Our LymphoStat-B collaborator is GlaxoSmithKline. We expect both Albuferon and LymphoStat-B to advance to Phase 3 clinical trials in 2006.

In June 2006, HGS announced that the U.S. Government has exercised its option under an existing contract to purchase 20,000 doses of ABthrax, for the treatment of anthrax disease. Under the contract, we will also complete the additional laboratory and clinical testing required to support the filing of a Biologics License Application with the U.S. Food and Drug Administration, and to support the use of ABthrax in the event of an emergency prior to FDA licensure. Other HGS compounds in clinical development include our three TRAIL receptor antibodies for the treatment of hematopoietic and solid malignancies, and our antibody to the CCR5 receptor for the treatment of HIV/AIDS.

We concentrate our internal product development efforts on new antibody drugs discovered through genomics-based research, and on new long-acting versions of existing protein drugs created using our albumin fusion technology. We rely on collaborations for the development of other products discovered using HGS technology, including small molecule drugs, additional protein and antibody drugs, gene therapy products and diagnostic products.

Manufacturing

HGS manufactures its own drugs for preclinical studies and clinical trials. We have completed the construction of a large-scale manufacturing facility to increase our capacity for protein and antibody drug production to support the clinical progress and eventual commercialization of our product candidates. We expect to complete the commissioning and validation of this facility in the second half of 2006.

Senior Management Team

HGS has assembled a highly capable management team with many years of broad-ranging experience. A Management Committee works closely with our Board of Directors, which is chaired by Argeris N. Karabelas, PhD., to set the Company’s strategy and guide its progress toward commercialization. Members of the Management Committee include: H. Thomas Watkins, President and Chief Executive Officer; James H. Davis, Ph.D., J.D., Executive Vice President and General Counsel; Barry A. Labinger, Executive Vice President and Chief Commercial Officer; David C. Stump, M.D., Executive Vice President, Research and Development; Timothy C. Barabe, Senior Vice President and Chief Financial Officer; Susan Bateson, Senior Vice President, Human Resources; and Curran M. Simpson, Senior Vice President, Operations.

HGS was founded in 1992 and is based in Rockville , Maryland , with approximately 880 employees. The Company’s common stock has been traded publicly since 1993 and is listed on the Nasdaq National Market System under the ticker symbol HGSI .

PRODUCTS IN CLINICAL DEVELOPMENT

The HGS clinical development pipeline includes treatments for hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. Our partners are conducting clinical trials of additional drugs to treat cardiovascular, metabolic and central nervous system diseases.

LEAD PRODUCTS

Two of the Company’s lead products, Albuferon® for chronic hepatitis C and LymphoStat-B® for systemic lupus erythematosus ( SLE ), have entered Phase 3 development. The third lead product, ABthrax™, is in late-stage development for inhalation anthrax.

Albuferon® (albinterferon alfa-2b)

Albuferon is a novel longer-acting form of interferon alpha that was created using the proprietary HGS albumin-fusion technology. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad range of cancers. HGS is currently conducting two pivotal Phase 3 clinical trials of Albuferon in combination with ribavirin: ACHIEVE 1 in treatment-naïve patients with genotype 1 chronic hepatitis C, and ACHIEVE 2/3 in treatment-naive patients with genotype 2 or 3 hepatitis C. ACHIEVE 1 and ACHIEVE 2/3, assuming that they are successful, will provide the pivotal data to support global marketing authorization applications for Albuferon, which HGS and Novartis expect to file in fall 2009. Albuferon requires half as many injections as Pegasys (peginterferon alfa-2a), the leading available long-acting interferon, and Phase 2 clinical results suggest that Albuferon could offer efficacy and safety comparable to Pegasys, with the potential for improved quality of life and fewer lost days of work during therapy. Assuming that Phase 2 results are confirmed in Phase 3, HGS believes that Albuferon could become the market-leading interferon in treatment regimens for chronic hepatitis C. Albuferon is being developed by HGS and Novartis under a worldwide co-development and commercialization agreement entered into in June 2006.


LymphoStat-B® (belimumab)

LymphoStat-B is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS®, which was discovered by HGS. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues. HGS is currently conducting two pivotal Phase 3 clinical trials of LymphoStat-B in patients with systemic lupus erythematosus ( SLE ): BLISS-76 and BLISS-52. The design of the two trials is similar, except for the duration of therapy, which is 76 weeks in BLISS-76 and 52 weeks in BLISS-52. The primary efficacy endpoint of both trials is the patient response rate at Week 52. Phase 2 clinical results in patients with active SLE suggest that LymphoStat-B achieved a sustained improvement in SLE disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care. Assuming that these results are confirmed in Phase 3, HGS believes that LymphoStat-B could become a breakthrough treatment for SLE. LymphoStat-B is being developed by HGS and GlaxoSmithKline (GSK) under a definitive worldwide co-development and commercialization agreement entered into in August 2006.


ABthrax™ (raxibacumab)

ABthrax is a human monoclonal antibody that blocks the binding to cell surfaces of Bacillus anthracis protective antigen, the key facilitator of anthrax toxicity. This prevents the anthrax toxin from entering and killing the cells. ABthrax is being developed under a contract with the U.S. Government, which was secured in June 2006. In December 2007, HGS announced study results that provide the scientific evidence required to establish the efficacy of ABthrax. The Company has also demonstrated that ABthrax was generally safe and well tolerated in two clinical trials in healthy adults. HGS plans to submit the final data package to BARDA and FDA by mid-2008 to support authorization for delivery to the Strategic National Stockpile, and is manufacturing ABthrax on schedule to begin delivery by fall.

PRODUCTS IN THE GSK PIPELINE

HGS has substantial financial rights to three products in the GSK clinical development pipeline. Two of these are genomics-derived small-molecule drugs discovered by GSK based on HGS technology. The third product is an albumin-fusion protein created by HGS.

Darapladib is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that has been identified in clinical trials as an independent risk factor for coronary heart disease and ischemic stroke. GSK has advanced darapladib to Phase 2/3 clinical trials for the treatment of atherosclerosis. Darapladib was discovered by GSK based on HGS technology, and it has the potential to be an important new treatment for the prevention of cardiovascular risk,

GSK649868 is a small-molecule orexin antagonist. Orexin is a hormone that plays an important role in the regulation of sleep-wake cycles. GSK649868 is in Phase 2 clinical development for the treatment of sleep disorders.

Syncria® (albiglutide) is a novel longer-acting form of glucagon-like peptide-1 (GLP-1). GLP-1 is a peptide hormone that acts to help maintain healthy blood sugar levels and to control appetite. Syncria was created using the HGS proprietary albumin fusion technology, and was licensed to GSK in October 2004. In May 2007, GSK initiated a Phase 2b randomized dose-ranging trial of Syncria in patients with type 2 diabetes.

Corporate Headquarters

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850-3338
Phone: (301) 309-8504
Fax: (301) 309-8512
http://www.hgsi.com

Transfer Agent

American Stock Transfer & Trust Company
59 Maiden Lane
New York, New York 10038
Telephone: (800) 937-5449 or (212) 936-5100
http://www.amstock.com

O/S: 131.43M
Float: 130.26M
% Held by Institutions: 92.00%

This Stock is down about 50% since the end of January. According to the Charts It looks like this stock might be ready for a bounce.

Looks like it going to finish green today as well as yesterday. I think its a good time to get in this one. This company is obviously oversold.

Chart is looking good. Looks good early today. Weak resistance @7.80 and then nothing til 9.40

I just picked up a few more shares today hoping that a pr comes out on this. It looks like we might close green for the 3rd straight day. With the stock price currently @ 6.50 this thing has alot of room to move up.It really has no resistance for a while and appears to be on the rebound after dropping about 50% in January. I did my DD on this and the charts are looking real good but i recommend everyone to do thier own DD. Appears to me it might be getting ready for a run as it is picking up momentum.

Looks like we are up early today. Looking good!!!